Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Sage Therapeutics, Inc. develops treatments for central nervous system disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Sage Therapeutics operates in the United States.
Website: sagerx.com



Growth: Good revenue growth rate 50.0%, there is acceleration compared to average historical growth rates 33.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -6 227.3%. On average the margin is decreasing steadily. Gross margin is high, +66.7%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -99.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 84.1% higher than minimum and 85.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -299.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: SAGE
Share price, USD:  (+0.5%)8.8
year average price 7.29  


year start price 10.99 2024-07-27

max close price 10.99 2024-07-27

min close price 4.78 2024-11-18

current price 8.80 2025-07-26
Common stocks: 59 912 378

Dividend Yield:  0.0%
EV / Sales: -31.1x
Margin (EBITDA LTM / Revenue): -6 227.3%
Fundamental value created in LTM:
Market Cap ($m): 527
Net Debt ($m): -869
EV (Enterprise Value): -342
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-01globenewswire.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)

2025-06-18businesswire.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

2025-06-17zacks.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

2025-06-17zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

2025-06-16businesswire.com

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

2025-04-29seekingalpha.com

Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript

2025-04-20accessnewswire.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

2025-04-13accessnewswire.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

2025-03-30accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect

2025-03-09accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-29 2024-07-31 2024-04-25 2024-02-14 2023-11-07 2023-08-07 2023-05-02 2023-02-16 2022-11-08
acceptedDate 2024-10-29 16:20:23 2024-07-31 16:15:30 2024-04-25 07:15:32 2024-02-14 07:20:39 2023-11-07 07:00:35 2023-08-07 07:20:50 2023-05-02 07:21:17 2023-02-16 07:31:44 2022-11-08 07:20:56
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 12M 9M 8M 78M 3M 2M 3M 3M 2M
costOfRevenue 5M 1M 1M 820 000 905 000 205 000 230 000 143 000 184 000
grossProfit 7M 7M 7M 77M 2M 2M 3M 3M 2M
grossProfitRatio 0.555 0.837 0.839 0.989 0.667 0.917 0.93 0.95 0.894
researchAndDevelopmentExpenses 55M 63M 72M 64M 102M 97M 93M 89M 82M
generalAndAdministrativeExpenses 53M 56M 53M 55M 78M 75M 66M 67M 61M
sellingAndMarketingExpenses 0 0 -597 000 -76 000 0 76 000 0 0 0
sellingGeneralAndAdministrativeExpenses 53M 56M 52M 55M 78M 76M 66M 67M 61M
otherExpenses 0 15 000 -12 000 -99 000 -55 000 -41 000 -188 000 -37 000 0
operatingExpenses 108M 119M 124M 119M 180M 173M 159M 157M 143M
costAndExpenses 113M 120M 125M 120M 181M 173M 159M 157M 143M
interestIncome 8M 8M 9M 9M 10M 10M 9M 7M 4M
interestExpense 0 0 0 9M 0 0 -9M 7M 4M
depreciationAndAmortization 255 000 311 000 336 000 43 812 330 000 331 000 323 000 290 000 278 000
ebitda -101M -111M -117M -42M -144M -170M -155M -154M -133M
ebitdaratio -8.525 -12.825 -14.774 -0.54 -53.137 -68.899 -47.198 -53.718 -76.434
operatingIncome -101M -111M -117M -42M -212M -170M -155M -154M -141M
operatingIncomeRatio -8.525 -12.861 -14.816 -0.54 -78 -68.899 -47.198 -53.718 -81.357
totalOtherIncomeExpensesNet 8M 8M 9M 114 000 -34M -41 000 9M 7M 4M
incomeBeforeTax -94M -103M -108M -33M -202M -160M -147M -147M -137M
incomeBeforeTaxRatio -7.881 -11.885 -13.729 -0.419 -74.238 -64.804 -44.574 -51.36 -78.967
incomeTaxExpense 0 0 292 724 -10M 23M -11M -9M -14M 0
netIncome -94M -103M -108M -33M -202M -160M -138M -133M -137M
netIncomeRatio -7.881 -11.885 -13.729 -0.419 -74.238 -64.804 -41.951 -46.529 -78.967
eps -1.53 -1.7 -1.8 -0.55 -3.37 -2.68 -2.32 -2.24 -2.31
epsdiluted -1.53 -1.7 -1.8 -0.55 -3.37 -2.68 -2.32 -2.24 -2.31
weightedAverageShsOut 61M 61M 60M 60M 60M 60M 60M 59M 59M
weightedAverageShsOutDil 61M 61M 60M 60M 60M 60M 60M 59M 59M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-29 2024-07-31 2024-04-25 2024-02-14 2023-11-07 2023-08-07 2023-05-02 2023-02-16 2022-11-08
acceptedDate 2024-10-29 16:20:23 2024-07-31 16:15:30 2024-04-25 07:15:32 2024-02-14 07:20:39 2023-11-07 07:00:35 2023-08-07 07:20:50 2023-05-02 07:21:17 2023-02-16 07:31:44 2022-11-08 07:20:56
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 100M 101M 174M 71M 149M 121M 207M 163M 200M
shortTermInvestments 470M 547M 544M 682M 727M 881M 923M 1 110M 1 194M
cashAndShortTermInvestments 569M 648M 718M 753M 876M 1 003M 1 130M 1 272M 1 394M
netReceivables 15M 0 14M 83M 23M 15M 15M 14M 18M
inventory 0 0 1 1M 1 -61M -15M -64M 0
otherCurrentAssets 21M 40M 23M 32M 35M 46M 74M 51M 53M
totalCurrentAssets 605M 687M 755M 869M 933M 1 003M 1 203M 1 272M 1 465M
propertyPlantEquipmentNet 12M 2M 4M 6M 8M 10M 12M 13M 15M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 2M 0 1M 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 5M 8M 6M 7M 7M 70M 6M 71M 6M
totalNonCurrentAssets 17M 10M 12M 13M 16M 80M 17M 84M 21M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 622M 697M 768M 882M 950M 1 082M 1 221M 1 356M 1 486M
accountPayables 7M 9M 6M 10M 11M 9M 12M 19M 7M
shortTermDebt 166 000 3M 3M 5M 7M 8M 8M 8M 8M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 53M 58M 52M 67M 115M 80M 65M 73M 85M
totalCurrentLiabilities 60M 69M 62M 83M 133M 97M 85M 99M 100M
longTermDebt 10M 0 0 0 0 1M 3M 4M 6M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 102 000 102 000 100 000 100 000
totalNonCurrentLiabilities 10M 0 0 0 0 1M 3M 5M 6M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 10M 1M 3M 5M 7M 9M 10M 12M 14M
totalLiabilities 71M 69M 62M 83M 133M 98M 88M 104M 106M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 6000 6000 6000 6000 6000 6000 6000 6000 6000
retainedEarnings -2 875M -2 781M -2 678M -2 570M -2 537M -2 335M -2 175M -2 028M -1 881M
accumulatedOtherComprehensiveIncomeLoss 901 000 -691 000 -787 000 -814 000 -4M -6M -5M -10M -15M
othertotalStockholdersEquity 3 425M 3 410M 3 385M 3 370M 3 357M 3 325M 3 313M 3 291M 3 276M
totalStockholdersEquity 552M 628M 706M 800M 817M 984M 1 133M 1 253M 1 380M
totalEquity 552M 628M 706M 800M 817M 984M 1 133M 1 253M 1 380M
totalLiabilitiesAndStockholdersEquity 622M 697M 768M 882M 950M 1 082M 1 221M 1 356M 1 486M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 622M 697M 768M 882M 950M 1 082M 1 221M 1 356M 1 486M
totalInvestments 470M 547M 546M 682M 727M 881M 923M 1 110M 0
totalDebt 10M 1M 3M 5M 7M 9M 10M 12M 14M
netDebt -89M -100M -171M -66M -142M -113M -196M -151M -186M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-29 2024-07-31 2024-04-25 2024-02-14 2023-11-07 2023-08-07 2023-05-02 2023-02-16 2022-11-08
acceptedDate 2024-10-29 16:20:23 2024-07-31 16:15:30 2024-04-25 07:15:32 2024-02-14 07:20:39 2023-11-07 07:00:35 2023-08-07 07:20:50 2023-05-02 07:21:17 2023-02-16 07:31:44 2022-11-08 07:20:56
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -94M -103M -108M -33M -202M -160M -147M -147M -137M
depreciationAndAmortization 255 000 311 000 336 000 409 000 330 000 331 000 323 000 290 000 278 000
deferredIncomeTax 0 0 0 0 0 0 0 0 0
stockBasedCompensation 14M 17M 14M 13M 29M 12M 20M 15M 13M
changeInWorkingCapital -1M 7M 58M -106M 42M 21M -24M 6M 4M
accountsReceivables -5M 566 000 73M -60M -7M 0 0 0 0
inventory 0 0 0 60M 7M 0 0 0 0
accountsPayables -2M 2M -4M -818 000 2M -3M -7M 12M 2M
otherWorkingCapital 5M 4M -10M -105M 40M 24M 7M -6M 0
otherNonCashItems -2M 13M -56M 6M -5M -4M -3M -1M 1M
netCashProvidedByOperatingActivities -82M -80M -38M -120M -136M -132M -154M -127M -119M
investmentsInPropertyPlantAndEquipment 0 0 0 112 000 -328 000 -112 000 -225 000 -282 000 -364 000
acquisitionsNet 0 0 0 -42M -161M 0 0 0 0
purchasesOfInvestments -102M -198M -62M -135M -70M -233M -157M -199M -251M
salesMaturitiesOfInvestments 183M 198M 201M 177M 231M 278M 352M 289M 363M
otherInvestingActivites 0 -386 000 139M 42M 161M 0 0 0 0
netCashUsedForInvestingActivites 81M -386 000 139M 42M 160M 46M 195M 90M 111M
debtRepayment 0 0 0 -7M -3M 0 0 0 0
commonStockIssued 1000 8M 2M -7M 3M 0 0 0 0
commonStockRepurchased 3000 -1000 -2000 -262 000 -4000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 1M 8M -2000 -262 000 10M 847 000 3M 29 000 1M
netCashUsedProvidedByFinancingActivities 1M 8M 2M -262 000 3M 847 000 3M 29 000 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash 1M -73M 102M -78M 27M -85M 44M -37M -7M
cashAtEndOfPeriod 102M 101M 174M 72M 150M 123M 208M 164M 201M
cashAtBeginningOfPeriod 101M 174M 72M 150M 123M 208M 164M 201M 208M
operatingCashFlow -82M -80M -38M -120M -136M -132M -154M -127M -119M
capitalExpenditure 0 0 0 112 000 -328 000 -112 000 -225 000 -282 000 -364 000
freeCashFlow -82M -80M -38M -119M -136M -132M -154M -127M -119M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-07 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-29 20:05 ET
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
2024-10-17 11:00 ET
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
2024-10-15 10:30 ET
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
2024-10-08 10:30 ET
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
2024-09-26 11:00 ET
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
2024-07-31 20:05 ET
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
2024-07-24 10:30 ET
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
2024-07-17 10:30 ET
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
2024-06-11 10:30 ET
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
2024-06-05 10:30 ET
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-07 10:30 ET
Sage Therapeutics to Participate in Upcoming May Investor Conferences
2024-04-25 10:30 ET
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
2024-04-17 10:30 ET
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
2024-04-11 10:30 ET
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
2024-02-28 11:30 ET
Sage Therapeutics to Present at Upcoming March Investor Conferences
2024-02-14 11:30 ET
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
2024-01-31 11:30 ET
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
2024-01-08 11:32 ET
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-08 11:30 ET
Sage Therapeutics Announces Changes to Board of Directors
2024-01-02 11:30 ET
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
2023-11-08 11:30 ET
Sage Therapeutics to Present at Upcoming November Investor Conferences
2023-11-07 11:30 ET
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2023-10-24 10:30 ET
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
2023-10-18 10:30 ET
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
2023-09-06 10:30 ET
Sage Therapeutics to Present at Upcoming September Investor Conferences
2023-08-31 10:30 ET
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
2023-08-07 10:30 ET
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2023-08-05 02:45 ET
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
2023-08-05 02:42 ET
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
2023-06-05 10:30 ET
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-03 10:30 ET
Sage Therapeutics to Present at Upcoming May Investor Conferences
2023-05-02 10:30 ET
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2023-04-18 10:30 ET
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
2023-03-22 10:30 ET
Sage Therapeutics to Present at the Stifel 2023 CNS Days
2023-03-16 10:30 ET
Sage Therapeutics Appoints Jessica Federer to Board of Directors
2023-03-08 11:30 ET
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
2023-02-28 21:05 ET
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
2023-02-22 11:30 ET
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
2023-02-16 11:30 ET
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
2023-02-02 11:30 ET
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
2023-01-08 17:00 ET
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
2023-01-03 11:30 ET
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
2022-11-23 11:30 ET
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
2022-11-09 11:30 ET
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
2022-11-08 11:30 ET
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
2022-11-01 11:30 ET
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
2022-10-25 10:30 ET
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
2022-09-02 10:30 ET
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-02 10:30 ET
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
2022-08-01 10:30 ET
Sage Therapeutics to Present at Upcoming August Investor Conferences
2022-07-19 10:30 ET
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
2022-06-02 10:30 ET
Sage Therapeutics to Present at Upcoming June Investor Conferences
2022-05-04 10:30 ET
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
2022-05-03 10:30 ET
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
2022-04-19 10:30 ET
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
2022-04-01 10:30 ET
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
2022-03-22 10:30 ET
Sage Therapeutics to Present at 2022 Stifel CNS Days
2022-03-15 10:30 ET
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
2022-02-28 21:05 ET
Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
2022-02-24 11:30 ET
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
2022-02-10 11:30 ET
Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
2022-01-04 11:30 ET
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
2021-12-14 11:30 ET
Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises

SEC forms

Show financial reports only

SEC form 8
2025-06-16 11:55 ET
Sage Therapeutics published news for 2025 q1
SEC form 8
2025-06-16 11:55 ET
Sage Therapeutics published news for 2025 q1
SEC form 8
2025-06-16 11:55 ET
Sage Therapeutics published news for 2025 q1
SEC form 10
2025-04-29 20:18 ET
Sage Therapeutics reported for 2025 q1
SEC form 10
2025-04-29 00:00 ET
Sage Therapeutics reported for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Sage Therapeutics reported for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Sage Therapeutics published news for 2025 q1
SEC form 10
2025-02-11 21:14 ET
Sage Therapeutics reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Sage Therapeutics reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Sage Therapeutics published news for 2024 q4
SEC form 10
2025-02-11 00:00 ET
Sage Therapeutics reported for 2024 q4
SEC form 8
2025-01-27 14:28 ET
Sage Therapeutics published news for 2024 q4
SEC form 8
2025-01-27 14:28 ET
Sage Therapeutics published news for 2024 q4
SEC form 10
2024-10-29 16:20 ET
Sage Therapeutics reported for 2024 q3
SEC form 8
2024-10-29 16:10 ET
Sage Therapeutics reported for 2024 q3
SEC form 8
2024-10-29 16:10 ET
Sage Therapeutics published news for 2024 q3
SEC form 10
2024-10-29 00:00 ET
Sage Therapeutics reported for 2024 q3
SEC form 10
2024-07-31 16:15 ET
Sage Therapeutics reported for 2024 q2
SEC form 8
2024-07-31 16:10 ET
Sage Therapeutics published news for 2024 q2
SEC form 8
2024-07-31 16:10 ET
Sage Therapeutics reported for 2024 q2
SEC form 10
2024-07-31 00:00 ET
Sage Therapeutics reported for 2024 q2
SEC form 10
2024-04-25 07:15 ET
Sage Therapeutics reported for 2024 q1
SEC form 8
2024-04-25 06:46 ET
Sage Therapeutics published news for 2024 q1
SEC form 8
2024-04-25 06:46 ET
Sage Therapeutics reported for 2024 q1
SEC form 10
2024-04-25 00:00 ET
Sage Therapeutics reported for 2024 q1
SEC form 8
2024-02-14 00:00 ET
Sage Therapeutics published news for 2023 q4
SEC form 10
2024-02-14 00:00 ET
Sage Therapeutics reported for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Sage Therapeutics reported for 2023 q4
SEC form 10
2023-11-07 07:00 ET
Sage Therapeutics reported for 2023 q3
SEC form 8
2023-11-07 06:46 ET
Sage Therapeutics reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Sage Therapeutics published news for 2023 q3
SEC form 10
2023-08-07 07:20 ET
Sage Therapeutics reported for 2023 q2
SEC form 6
2023-08-07 06:45 ET
Sage Therapeutics reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Sage Therapeutics published news for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Sage Therapeutics published news for 2023 q2
SEC form 6
2023-06-16 16:06 ET
Sage Therapeutics published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Sage Therapeutics published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Sage Therapeutics reported for 2023 q1
SEC form 6
2023-03-16 06:37 ET
Sage Therapeutics published news for 2022 q4
SEC form 10
2023-02-16 07:31 ET
Sage Therapeutics reported for 2022 q4
SEC form 6
2023-02-16 06:45 ET
Sage Therapeutics published news for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Sage Therapeutics reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
Sage Therapeutics reported for 2022 q4
SEC form 6
2023-02-06 06:45 ET
Sage Therapeutics published news for 2022 q4
SEC form 6
2023-01-09 06:09 ET
Sage Therapeutics published news for 2022 q4
SEC form 6
2022-12-06 06:51 ET
Sage Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 07:20 ET
Sage Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 06:45 ET
Sage Therapeutics published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Sage Therapeutics reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Sage Therapeutics reported for 2022 q3
SEC form 10
2022-08-02 07:20 ET
Sage Therapeutics reported for 2022 q2
SEC form 6
2022-08-02 06:45 ET
Sage Therapeutics published news for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Sage Therapeutics reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Sage Therapeutics reported for 2022 q2
SEC form 6
2022-07-14 16:08 ET
Sage Therapeutics published news for 2022 q2
SEC form 6
2022-06-21 16:41 ET
Sage Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 07:01 ET
Sage Therapeutics published news for 2022 q1
SEC form 6
2022-06-01 07:16 ET
Sage Therapeutics published news for 2022 q1
SEC form 10
2022-05-03 07:20 ET
Sage Therapeutics reported for 2022 q1
SEC form 6
2022-05-03 06:45 ET
Sage Therapeutics published news for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Sage Therapeutics reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Sage Therapeutics reported for 2022 q1
SEC form 6
2022-04-28 16:25 ET
Sage Therapeutics published news for 2022 q1
SEC form 10
2022-02-24 07:22 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 06:45 ET
Sage Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Sage Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2022-02-16 07:00 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 07:31 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2021-12-01 07:00 ET
Sage Therapeutics published news for 2021 q3
SEC form 6
2021-11-02 07:30 ET
Sage Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 07:22 ET
Sage Therapeutics published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Sage Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Sage Therapeutics published news for 2021 q3
SEC form 6
2021-10-19 08:01 ET
Sage Therapeutics published news for 2021 q3
SEC form 10
2021-08-03 07:20 ET
Sage Therapeutics published news for 2021 q2
SEC form 6
2021-08-03 07:01 ET
Sage Therapeutics published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Sage Therapeutics published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Sage Therapeutics published news for 2021 q2
SEC form 6
2021-06-15 06:50 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-06-10 16:05 ET
Sage Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 07:20 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 07:14 ET
Sage Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Sage Therapeutics published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 16:06 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-04-12 07:17 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-03-18 06:55 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2021-03-17 08:04 ET
Sage Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 07:15 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 06:46 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2021-01-07 16:14 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2020-12-31 16:05 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-12-16 07:00 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-11-27 07:38 ET
Sage Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 07:15 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 07:00 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-10-15 09:14 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-10-01 16:05 ET
Sage Therapeutics published news for 2020 q3